~~<i id='5777B01F5F'><strike id='5777B01F5F'><tt id='5777B01F5F'><pre id='5777B01F5F'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

knowledge

author：entertainment 2025-08-26 23:45:42 - browse：1

LONDON — GSK said Tuesday it would purchase the asthma-focused drug developer Aiolos Bio for $1 billion upfront, the latest in a string of pharma acquisitions that are bolstering hopes for the industry’s year ahead.

The deal includes up to another $400 million in payments if certain milestones are met.

Aiolos was launched just last year, based in both San Francisco and London. The company, which announced a $245 million Series A round in October, has been readying a Phase 2 trial of its candidate AIO-001 in adult asthma.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： Biotech investment managers search for lucrative opportunities

leisure time

hotspot

focus

hotspot

leisure time

hotspot

Whyarerichbiotechscuttingcosts?HasJPMWeekalreadywornoff?Andwhat’sgoingtomovemarketsin2024?Wecoverall

WSS

Readout LOUD podcast, live from the STAT Breakthrough Summit East

Think you might have Covid

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

Mirador, a new biotech startup, launches with $400 million

What Kate Middleton's cancer revelation might teach the world

This gene therapy has record $4.25 million price. It's saved children.

hotspot

knowledge

leisure time

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

The tragedy of Johnson & Johnson’s Covid vaccine

Medicare details structure of new drug price negotiation program

How digital therapeutics firms are pivoting after Pear's bankruptcy

Medical records are filled with copy

Texas board proposes rules on abortion law emergency exemption

The cancer drug shortage isn’t new — and neither are the solutions

How digital therapeutics firms are pivoting after Pear's bankruptcy

Duchenne breakthrough therapy leaves behind pioneering families

Surgeons perform first xenotransplant using CRISPR'd pig kidney

hotspot

How digital therapeutics firms are pivoting after Pear's bankruptcy

Erich Jarvis studies song birds to learn about human stuttering

This gene therapy has record $4.25 million price. It's saved children.

Readout LOUD podcast, live from the STAT Breakthrough Summit East

New brain studies show LSD's effects on the brain in full color

Yancopoulos of Regeneron works to expand Dupixent success

focus

hotspot

leisure time

hotspot